Compare ONC & FMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | FMX |
|---|---|---|
| Founded | 2010 | 1890 |
| Country | Switzerland | Mexico |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 41.4B |
| IPO Year | 2015 | 1998 |
| Metric | ONC | FMX |
|---|---|---|
| Price | $416.47 | $131.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 15 |
| Target Price | ★ $465.00 | $135.93 |
| AVG Volume (30 Days) | 442.0K | ★ 793.7K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 5.12% |
| EPS Growth | ★ 140.43 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $238,387,000.00 | N/A |
| Revenue This Year | $29.05 | $7.78 |
| Revenue Next Year | $15.06 | $7.89 |
| P/E Ratio | $743.85 | ★ $40.94 |
| Revenue Growth | ★ 22179.16 | N/A |
| 52 Week Low | $253.95 | $92.55 |
| 52 Week High | $424.73 | $141.47 |
| Indicator | ONC | FMX |
|---|---|---|
| Relative Strength Index (RSI) | 67.27 | 64.47 |
| Support Level | $341.67 | $121.26 |
| Resistance Level | N/A | $134.52 |
| Average True Range (ATR) | 10.70 | 2.95 |
| MACD | 4.37 | 0.31 |
| Stochastic Oscillator | 88.77 | 82.87 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up over 70% of total company revenue and over 90% of profits in 2025.